NotíciasBenzingaReported Sunday, AbbVie’s SKYRIZI Shows Sustained Endoscopic Outcomes Through 144 Weeks In Crohn’s And 74.5% Fistula Resolution At Five Years, While RINVOQ Real-World Data Show Remission In Advanced Crohn’s Reported Sunday, AbbVie’s SKYRIZI Shows Sustained Endoscopic Outcomes Through 144 Weeks In Crohn’s And 74.5% Fistula Resolution At Five Years, While RINVOQ Real-World Data Show Remission In Advanced Crohn’s Benzinga 2026.10.12 07:03 (GMT+0) Abrir em Benzinga Outras notícias Maximus anuncia aquisição da Agile Defense por US$ 660 milhões Century Fire, da FirstService, adquire a A&A Fire Protection FreightCar reduz perspectivas para 2026 após cancelar pedido de vagões-tanque Karooooo registra crescimento de 25% na receita no segundo trimestre Tradeweb anuncia aquisição da Trumid por US$ 1,97 bilhão CEO da Home Bancorp se aposenta e Guidry assume o cargo
